Matches in SemOpenAlex for { <https://semopenalex.org/work/W2046923188> ?p ?o ?g. }
Showing items 1 to 97 of
97
with 100 items per page.
- W2046923188 endingPage "3815" @default.
- W2046923188 startingPage "3812" @default.
- W2046923188 abstract "Epithelial ovarian cancer (EOC) is the most lethal of the gynecologic malignancies, largely due to the advanced stage at diagnosis in most patients. Standard treatment for EOC is surgical debulking followed by platinum-based chemotherapy. While the majority of ovarian cancer patients will respond to initial chemotherapy, most will ultimately relapse. The major focus of current clinical trials for treatment of recurrent ovarian cancer is the use of targeted biologic agents. Folate receptor alpha (FRα) is upregulated in majority of EOC and correlated with tumor stage and grade. It is hypothesized that the presence of overexpressed FRα correlates with the propagation rate of the tumors. FRα is largely absent from normal tissue, making it an attractive therapeutic target. Farletuzumab (MORAb-003), a humanized monoclonal antibody against FRα, has shown antitumor activity in preclinical xenograft models. A Phase 1 dose escalation study did not demonstrate dose-limiting toxicities, or severe adverse effects. A phase 2 efficacy and safety study of farletuzumab with carboplatin and taxane in patients with platinum-sensitive EOC in first relapse, have shown an improved response rate and time to progression compared with historical controls. Recently, preliminary safety data from a phase 1 trial reported that the combination of farletuzumab, carboplatin and PLD has an acceptable safety profile in patients with platinum- sensitive EOC following first or second relapse. Two randomized, double-blind, placebo-controlled Phase 3 studies with farletuzumab plus chemotherapy have been done. A trial of: farletuzumab with weekly paclitaxel in platinum-resistant EOC closed in December 2011 with full report pending. A second trial of farletuzumab with carboplatin and taxane in platinum-sensitive EOC in first relapse is slated to complete accrual in early 2012. Results from these trials will help define the role of farletuzumab in EOC." @default.
- W2046923188 created "2016-06-24" @default.
- W2046923188 creator A5075192326 @default.
- W2046923188 creator A5090143508 @default.
- W2046923188 date "2012-08-01" @default.
- W2046923188 modified "2023-09-23" @default.
- W2046923188 title "Role of Farletuzumab in Epithelial Ovarian Carcinoma" @default.
- W2046923188 cites W1524027952 @default.
- W2046923188 cites W1680408639 @default.
- W2046923188 cites W1933750051 @default.
- W2046923188 cites W1970832325 @default.
- W2046923188 cites W1971341208 @default.
- W2046923188 cites W1992819900 @default.
- W2046923188 cites W2006213902 @default.
- W2046923188 cites W2015217255 @default.
- W2046923188 cites W2023519068 @default.
- W2046923188 cites W2049490668 @default.
- W2046923188 cites W2050289293 @default.
- W2046923188 cites W2060459188 @default.
- W2046923188 cites W2082029694 @default.
- W2046923188 cites W2090859762 @default.
- W2046923188 cites W2103953940 @default.
- W2046923188 cites W2124979764 @default.
- W2046923188 cites W2126333580 @default.
- W2046923188 cites W2138035969 @default.
- W2046923188 cites W2158734599 @default.
- W2046923188 cites W2162114522 @default.
- W2046923188 doi "https://doi.org/10.2174/138161212802002698" @default.
- W2046923188 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3576870" @default.
- W2046923188 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22591419" @default.
- W2046923188 hasPublicationYear "2012" @default.
- W2046923188 type Work @default.
- W2046923188 sameAs 2046923188 @default.
- W2046923188 citedByCount "24" @default.
- W2046923188 countsByYear W20469231882012 @default.
- W2046923188 countsByYear W20469231882013 @default.
- W2046923188 countsByYear W20469231882014 @default.
- W2046923188 countsByYear W20469231882015 @default.
- W2046923188 countsByYear W20469231882016 @default.
- W2046923188 countsByYear W20469231882017 @default.
- W2046923188 countsByYear W20469231882019 @default.
- W2046923188 countsByYear W20469231882020 @default.
- W2046923188 countsByYear W20469231882021 @default.
- W2046923188 crossrefType "journal-article" @default.
- W2046923188 hasAuthorship W2046923188A5075192326 @default.
- W2046923188 hasAuthorship W2046923188A5090143508 @default.
- W2046923188 hasBestOaLocation W20469231882 @default.
- W2046923188 hasConcept C121608353 @default.
- W2046923188 hasConcept C126322002 @default.
- W2046923188 hasConcept C143998085 @default.
- W2046923188 hasConcept C2776694085 @default.
- W2046923188 hasConcept C2777292972 @default.
- W2046923188 hasConcept C2777511904 @default.
- W2046923188 hasConcept C2778239845 @default.
- W2046923188 hasConcept C2780427987 @default.
- W2046923188 hasConcept C2781100745 @default.
- W2046923188 hasConcept C2781451048 @default.
- W2046923188 hasConcept C530470458 @default.
- W2046923188 hasConcept C535046627 @default.
- W2046923188 hasConcept C71924100 @default.
- W2046923188 hasConceptScore W2046923188C121608353 @default.
- W2046923188 hasConceptScore W2046923188C126322002 @default.
- W2046923188 hasConceptScore W2046923188C143998085 @default.
- W2046923188 hasConceptScore W2046923188C2776694085 @default.
- W2046923188 hasConceptScore W2046923188C2777292972 @default.
- W2046923188 hasConceptScore W2046923188C2777511904 @default.
- W2046923188 hasConceptScore W2046923188C2778239845 @default.
- W2046923188 hasConceptScore W2046923188C2780427987 @default.
- W2046923188 hasConceptScore W2046923188C2781100745 @default.
- W2046923188 hasConceptScore W2046923188C2781451048 @default.
- W2046923188 hasConceptScore W2046923188C530470458 @default.
- W2046923188 hasConceptScore W2046923188C535046627 @default.
- W2046923188 hasConceptScore W2046923188C71924100 @default.
- W2046923188 hasIssue "25" @default.
- W2046923188 hasLocation W20469231881 @default.
- W2046923188 hasLocation W20469231882 @default.
- W2046923188 hasLocation W20469231883 @default.
- W2046923188 hasLocation W20469231884 @default.
- W2046923188 hasOpenAccess W2046923188 @default.
- W2046923188 hasPrimaryLocation W20469231881 @default.
- W2046923188 hasRelatedWork W1982849070 @default.
- W2046923188 hasRelatedWork W2006318969 @default.
- W2046923188 hasRelatedWork W2025352271 @default.
- W2046923188 hasRelatedWork W2053778437 @default.
- W2046923188 hasRelatedWork W2311734504 @default.
- W2046923188 hasRelatedWork W2320097775 @default.
- W2046923188 hasRelatedWork W2415960870 @default.
- W2046923188 hasRelatedWork W2503184010 @default.
- W2046923188 hasRelatedWork W2931860768 @default.
- W2046923188 hasRelatedWork W59268075 @default.
- W2046923188 hasVolume "18" @default.
- W2046923188 isParatext "false" @default.
- W2046923188 isRetracted "false" @default.
- W2046923188 magId "2046923188" @default.
- W2046923188 workType "article" @default.